Login | Register

Aubagio (teriflunomide) Approved For Multiple Sclerosis Treatment, FDA



Aubagio (teriflunomide), a once-daily tablet for adults with relapsing forms of MS (multiple sclerosis), has been approved by the US Food and Drug Administration (FDA). According to experts, the Multiple Sclerosis prescribing market is worth $12 billion annually. If Aubagio becomes popular, it has the potential to become a major earner for its makers, Sanofi-Aventis…

Leave a Reply

Your email address will not be published. Required fields are marked *